Anti-L-selectin monoclonal antibodies - PDL BioPharma

Drug Profile

Anti-L-selectin monoclonal antibodies - PDL BioPharma

Alternative Names: Anti-L-selectin monoclonal antibody DREG 200 - PDL BioPharma; Anti-L-selectin monoclonal antibody DREG 55; Aselizumab; BNP 001; DREG 200 - PDL BioPharma; DREG 55; hDREG-200 - PDL BioPharma; hDREG-55; Hu DREG 55; SMART anti-L-selectin antibodies

Latest Information Update: 24 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action L-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Shock
  • Discontinued Adult respiratory distress syndrome; Crohn's disease; Psoriasis; Reperfusion injury

Most Recent Events

  • 22 May 2006 No development reported - Preclinical for Shock in USA (unspecified route)
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
  • 18 Aug 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the Skin disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top